Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $23.00 target price on the stock. Needham & Company LLC's target price suggests a potential upside of 96.08% from the company's current price.

A number of other equities research analysts have also weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They set a "buy" rating and a $21.00 price objective on the stock. Wedbush restated an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Cantor Fitzgerald started coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set an "overweight" rating and a $23.00 price target on the stock. Finally, TD Cowen initiated coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a "buy" rating on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artiva Biotherapeutics has a consensus rating of "Buy" and a consensus target price of $21.25.

Artiva Biotherapeutics Trading Down 10.3 %

Shares of ARTV stock traded down $1.34 during trading hours on Wednesday, hitting $11.73. The stock had a trading volume of 16,085 shares, compared to its average volume of 140,010. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31. The business has a 50-day simple moving average of $12.55.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Thursday, August 29th. The company reported ($19.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($18.03). As a group, research analysts predict that Artiva Biotherapeutics will post -4.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

An institutional investor recently bought a new position in Artiva Biotherapeutics stock. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 40,293 shares of the company's stock, valued at approximately $623,000. Charles Schwab Investment Management Inc. owned 0.17% of Artiva Biotherapeutics at the end of the most recent quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.